SYK reported as an oncogene in B cell leukemia and lymphomas [33], head and neck cancer [18], ovarian cancer [34] and retinoblastoma [35], has made this kinase a popular target for the development of therapeutic agents. This evidence concerns the gene SYK and ovarian carcinoma.